Simon R - Search Results

1

Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Matsui S, Simon R, Qu P, Shaughnessy JD Jr, Barlogie B, Crowley J. Matsui S, et al. Among authors: simon r. Clin Cancer Res. 2012 Nov 1;18(21):6065-73. doi: 10.1158/1078-0432.CCR-12-1206. Epub 2012 Aug 27. Clin Cancer Res. 2012. PMID: 22927484 Free PMC article.

2

Evaluating the efficiency of targeted designs for randomized clinical trials.

Simon R, Maitournam A. Simon R, et al. Clin Cancer Res. 2004 Oct 15;10(20):6759-63. doi: 10.1158/1078-0432.CCR-04-0496. Clin Cancer Res. 2004. PMID: 15501951

3

How to develop treatments for biologically heterogeneous "diseases".

Simon RM. Simon RM. Clin Cancer Res. 2012 Aug 1;18(15):4001-3. doi: 10.1158/1078-0432.CCR-12-1586. Epub 2012 Jun 7. Clin Cancer Res. 2012. PMID: 22679178 Free PMC article.

4

The cross-validated adaptive signature design.

Freidlin B, Jiang W, Simon R. Freidlin B, et al. Among authors: simon r. Clin Cancer Res. 2010 Jan 15;16(2):691-8. doi: 10.1158/1078-0432.CCR-09-1357. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068112

5

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.

Scher HI, Nasso SF, Rubin EH, Simon R. Scher HI, et al. Among authors: simon r. Clin Cancer Res. 2011 Nov 1;17(21):6634-40. doi: 10.1158/1078-0432.CCR-11-1105. Clin Cancer Res. 2011. PMID: 22046024 Free PMC article.

6

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Freidlin B, Simon R. Freidlin B, et al. Among authors: simon r. Clin Cancer Res. 2005 Nov 1;11(21):7872-8. doi: 10.1158/1078-0432.CCR-05-0605. Clin Cancer Res. 2005. PMID: 16278411

7

The use of genomics in clinical trial design.

Simon R. Simon R. Clin Cancer Res. 2008 Oct 1;14(19):5984-93. doi: 10.1158/1078-0432.CCR-07-4531. Clin Cancer Res. 2008. PMID: 18829477 Review.

8

Roadmap for developing and validating therapeutically relevant genomic classifiers.

Simon R. Simon R. J Clin Oncol. 2005 Oct 10;23(29):7332-41. doi: 10.1200/JCO.2005.02.8712. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145063 Review.

9

Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.

Rahma OE, Gammoh E, Simon RM, Khleif SN. Rahma OE, et al. Clin Cancer Res. 2014 Sep 15;20(18):4758-67. doi: 10.1158/1078-0432.CCR-13-2671. Epub 2014 Jul 18. Clin Cancer Res. 2014. PMID: 25037736 Free PMC article.

10

A comparison of phase II study strategies.

Hunsberger S, Zhao Y, Simon R. Hunsberger S, et al. Among authors: simon r. Clin Cancer Res. 2009 Oct 1;15(19):5950-5. doi: 10.1158/1078-0432.CCR-08-3205. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789306 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,197 results

Search Page

Filters